Clinical Trial Update: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SHR-1210 (tislelizumab) plus capecitabine for postoperative intrahepatic cholangiocarcinoma is active but not recruiting. The study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• SHR-1210 (tislelizumab) (tislelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING